Laroprovstat

 

Laroprovstat

CAS 2455427-91-3

MF C20H20F2N6O2 MW414.4 g/mol

1-[6-[[(1S,3S)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]-3-pyridinyl]pyridin-2-one

• 1-[6-[[(1S,3S)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]pyridin-3-yl]pyridin-2-one
• 6'-(((1S,3S)-3-((5-(Difluoromethoxy)pyrimidin-2-yl)amino)cyclopentyl)amino)-2H-[1,3'-bipyridin]-2-one
• 6'-{[(1S,3S)-3-{[5-(difluoromethoxy)pyrimidin-2-yl]amino}cyclopentyl]amino}-2H-[1,3'-bipyridin]-2-one

6'-{[(1S,3S)-3-{[5-(difluoromethoxy)pyrimidin-2-yl]amino}cyclopentyl]amino}-2H-[1,3'-bipyridin]-2-one
proprotein convertase subtilisin/kexin type 9 (PCSK9), inhibitor, antihyperlipidaemic, 9EEL3YMY29, PCSK9-IN-12, AZD 0780, AZD-0780

• OriginatorDogma Therapeutics
• DeveloperAstraZeneca; Parexel International; Quotient Sciences
• ClassAmines; Antihyperlipidaemics; Cardiovascular therapies; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Hepatoprotectants; Ketones; Pyridines; Pyrimidines; Small molecules; Vascular disorder therapies
• Mechanism of ActionPCSK9 protein inhibitors
• Phase IIIAtherosclerosis; Cardiovascular disorders; Dyslipidaemias; Hyperlipoproteinaemia type II
• Phase ILiver disorders
• 30 Dec 2025AstraZeneca completes a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT07216131),
• 10 Nov 2025AstraZeneca initiates enrolment in a phase I pharmacokinetics trial (In volunteers) in USA (PO)(NCT07216131),
• 29 Oct 2025AstraZeneca completes a phase I trial in Dyslipidaemias (Combination therapy) in USA, United Kingdom (PO) (NCT06742853)

SYN

US11248001,

PAT



PAT

• PCSK9 Inhibitors and Methods of Use ThereofPublication Number: US-2020231584-A1Priority Date: 2019-01-18
• Pcsk9 inhibitors and methods of use thereofPublication Number: US-2022220122-A1Priority Date: 2019-01-18
• Pcsk9 inhibitors and methods of use thereofPublication Number: WO-2024013209-A1Priority Date: 2022-07-13
• PCSK9 Inhibitors and Methods of Use ThereofPublication Number: US-2020291041-A1Priority Date: 2019-01-18
• Pcsk9 inhibitors and methods of use thereofPublication Number: WO-2020150473-A2Priority Date: 2019-01-18
• Pcsk9 inhibitors and methods of use thereofPublication Number: WO-2020150474-A1Priority Date: 2019-01-18
• PCSK9 inhibitors and methods of use thereofPublication Number: US-11248001-B2Priority Date: 2019-01-18Grant Date: 2022-02-15

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com



......

/////////laroprovstat, antihyperlipidaemic, 9EEL3YMY29, PCSK9-IN-12, AZD 0780, AZD-0780

#laroprovstat, #antihyperlipidaemic, #9EEL3YMY29, #PCSK9-IN-12, #AZD 0780, #AZD-0780

Laselipag

 

Laselipag

CAS 475085-57-5

MF C25H29N3O3 MW 419.52

2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid

{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acid
prostanoid receptor agonist, ACT-333679, ACT 333679, ACT333679, E9PC7N0DID, MRE 269

ACT-333679 is a member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension. It has a role as an orphan drug, a platelet aggregation inhibitor, a prostacyclin receptor agonist, a vasodilator agent and a drug metabolite. It is an aromatic amine, an ether, a member of pyrazines, a sulfonamide, a tertiary amino compound and a monocarboxylic acid.

SYN

SYN

PAT

• Heterocyclic compound derivatives and medicinesPublication Number: CA-2445344-CPriority Date: 2001-04-26Grant Date: 2011-07-26
• Heterocyclic compound derivatives and medicinesPublication Number: US-2004102436-A1Priority Date: 2001-04-26
• DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND MEDICINAL PRODUCTSPublication Number: DE-60217674-T2Priority Date: 2001-04-26Grant Date: 2007-10-11
• Heterocyclic compound derivatives and medicinesPublication Number: EP-1400518-B1Priority Date: 2001-04-26Grant Date: 2007-01-17
• Heterocyclic compound derivatives and medicinesPublication Number: US-7205302-B2Priority Date: 2001-04-26Grant Date: 2007-04-17
• Heterocyclic compound derivatives and medicinesPublication Number: CA-2445344-A1Priority Date: 2001-04-26
• Heterocyclic derivatives and pharmaceuticalsPublication Number: JP-4479152-B2Priority Date: 2001-04-26Grant Date: 2010-06-09
• DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND MEDICINESPublication Number: RU-2003134190-APriority Date: 2001-04-26
• Heterocyclic derivatives and drugsPublication Number: JP-WO2002088084-A1Priority Date: 2001-04-26
• DERIVATIVES OF HETEROCYCLIC COMPOUNDS AND MEDICINAL PRODUCTS CONTAINING THEMPublication Number: PT-1400518-EPriority Date: 2001-04-26
• Heterocyclic compound derivatives and medicinesPublication Number: EP-1400518-A1Priority Date: 2001-04-26
• DERIVATIVES OF HETEROCICLIC COMPOUNDS AND MEDICINES.Publication Number: ES-2276931-T3Priority Date: 2001-04-26Grant Date: 2007-07-01

AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com



......

//////laselipag, prostanoid receptor agonist, ACT-333679, ACT 333679, ACT333679, E9PC7N0DID, MRE 269

#laselipag, #prostanoid receptor agonist, #ACT-333679, #ACT 333679, #ACT333679, #E9PC7N0DID, #MRE 269